ArticleScientific reports2025
LBX1, ESR1, and ESR2 genes DNA methylation level in idiopathic scoliosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Idiopathic scoliosis (IS) is a multifactorial disease with a genetic and environmental background. Recent studies suggest that epigenetic modifications, such as DNA methylation, may contribute to the IS occurrence and course. The aim of this study was to evaluate the association of LBX1, ESR1, and ESR2 gene methylation levels with susceptibility to and severity of IS. The study group (N = 63) consisted of 56 female and 7 male IS patients. The patients were analyzed in two subgroups based on the Cobb angle: ≤ 75° (N = 36) and > 75° (N = 27). The control group (N = 30) consisted of 27 females and 3 males without IS (23 healthy females, 2 spondylolisthesis, 3 scoliosis from prior thoracotomy, and 2 patients with Scheuermann's disease). DNA was isolated from peripheral blood. The methylation of selected LBX1, ESR1, and ESR2 regions was evaluated with a pyrosequencing method. The methylation level was expressed as a percentage of methylated CpG sites. P-value < 0.05 was considered significant. The mean methylation of the LBX1 forward strand promoter region differed significantly between controls 25.81% and patients 20.77%, p = 0.0013. The methylation was significantly higher in controls in 11 of 15 CpG sites. The mean methylation of the ESR1 T-DMR2 region was 50.44% in controls and 54.68% in patients, p = 0.0003. The methylation was significantly lower in controls in 5 of 8 CpG sites. There was no significant difference in the mean methylation level in ESR2 exon 0 N 5.17% vs. 5.58%, p = 0.2057. However, the methylation level in 10 of 19 CpG sites was significantly lower in controls and higher in 4 of 19 CpG. We observed no differences in the methylation level within all analyzed regions of ESR1, ESR2, and LBX1 genes between IS patients with ≤ 75° of the Cobb angle versus > 75°. Significant differences in the LBX1, ESR1, and ESR2 methylation levels between IS patients and controls were identified. IS patients revealed lower LBX1 forward strand promoter region methylation levels compared to controls. No association was found between the LBX1, ESR1, or ESR2 methylation levels and the severity of IS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.